About this trial
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
Eligibility criteria
Qualifiers
Being between 18-65 years of age
Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
Not having previously used any medication for psychiatric purposes (drug-naive)
Not having any additional active psychiatric disorders besides PD at the current presentation
Disqualifiers
Taking any medication or supplement in the last month
Incomplete completion of sociodemographic and scale data
Not volunteering to participate in the study
Being between 18-65 years of age
Trial design
Treatments tested in this trial
- Not listed